Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,167

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

Open access
Roberts, Steven A, Lawrence, Michael S, Klimczak, Leszek J, Grimm, Sara A, Fargo, David, Stojanov, Petar, Kiezun, Adam, Kryukov, Gregory V, Carter, Scott L, Saksena, Gordon, Harris, Shawn, Shah, Ruchir R, Resnick, Michael A, Getz, Gad, Gordenin, Dmitry A·2013·Nature Genetics
DOI 10.1038/ng.2702
Open this paper in CoChat — free account

Abstract

Recent studies indicate that a subclass of APOBEC cytidine deaminases, which convert cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction, may induce mutation clusters in human tumors. We show here that throughout cancer genomes APOBEC-mediated mutagenesis is pervasive and correlates with APOBEC mRNA levels. Mutation clusters in whole-genome and exome data sets conformed to the stringent criteria indicative of an APOBEC mutation pattern. Applying these criteria to 954,247 mutations in 2,680 exomes from 14 cancer types, mostly from The Cancer Genome Atlas (TCGA), showed a significant presence of the APOBEC mutation pattern in bladder, cervical, breast, head and neck, and lung cancers, reaching 68% of all mutations in some samples. Within breast cancer, the HER2-enriched subtype was clearly enriched for tumors with the APOBEC mutation pattern, suggesting that this type of mutagenesis is functionally linked with cancer development. The APOBEC mutation pattern also extended to cancer-associated genes, implying that ubiquitous APOBEC-mediated mutagenesis is carcinogenic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ng.2702

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 46

  1. Loeb, L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075–3079 (1991).
  2. Luch, A. Nature and nurture—lessons from chemical carcinogenesis. Nat. Rev. Cancer 5, 113–125 (2005). · DOI · Paper page
  3. Conticello, S.G. Creative deaminases, self-inflicted damage, and genome evolution. Ann. NY Acad. Sci. 1267, 79–85 (2012). · DOI
  4. Pavri, R. & Nussenzweig, M.C. AID targeting in antibody diversity. Adv. Immunol. 110, 1–26 (2011). · DOI
  5. Smith, H.C., Bennett, R.P., Kizilyer, A., McDougall, W.M. & Prohaska, K.M. Functions and regulation of the APOBEC family of proteins. Semin. Cell Dev. Biol. 23, 258–268 (2012). · DOI · Paper page
  6. Suspène, R. et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc. Natl. Acad. Sci. USA 108, 4858–4863 (2011). · DOI · Paper page
  7. Shinohara, M. et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci. Rep. 2, 806 (2012). · DOI
  8. Burns, M.B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366–370 (2013). · DOI · Paper page
  9. Stephens, P. et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37, 590–592 (2005). · DOI · Paper page
  10. Beale, R.C. et al. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337, 585–596 (2004). · DOI · Paper page
  11. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012). · DOI · Paper page
  12. Roberts, S.A. et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 46, 424–435 (2012). · DOI · Paper page
  13. Drier, Y. et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 23, 228–235 (2013). · DOI
  14. Gibbs, P.E. & Lawrence, C.W. Novel mutagenic properties of abasic sites in Saccharomyces cerevisiae. J. Mol. Biol. 251, 229–236 (1995). · DOI
  15. Simonelli, V., Narciso, L., Dogliotti, E. & Fortini, P. Base excision repair intermediates are mutagenic in mammalian cells. Nucleic Acids Res. 33, 4404–4411 (2005). · DOI
  16. Chan, K. et al. Base damage within single-strand DNA underlies in vivo hypermutability induced by a ubiquitous environmental agent. PLoS Genet. 8, e1003149 (2012). · DOI
  17. Senavirathne, G. et al. Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution. J. Biol. Chem. 287, 15826–15835 (2012). · DOI
  18. Chelico, L., Pham, P. & Goodman, M.F. Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat. Struct. Mol. Biol. 16, 454–455, author reply 455–456 (2009). · doi:10.1038/nsmb0509-454
  19. Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012). · DOI · Paper page
  20. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011). · DOI · Paper page
  21. Bass, A.J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964–968 (2011). · DOI · Paper page
  22. Shammas, M.A. et al. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 113, 2290–2297 (2009). · DOI
  23. Liu, P., Carvalho, C.M., Hastings, P.J. & Lupski, J.R. Mechanisms for recurrent and complex human genomic rearrangements. Curr. Opin. Genet. Dev. 22, 211–220 (2012). · DOI · Paper page
  24. Parker, J.S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009). · DOI · Paper page
  25. Landry, S., Narvaiza, I., Linfesty, D.C. & Weitzman, M.D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 12, 444–450 (2011). · DOI · Paper page
  26. Carter, H. et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 69, 6660–6667 (2009). · DOI · Paper page
  27. Douville, C. et al. CRAVAT: Cancer-Related Analysis of VAriants Toolkit. Bioinformatics 29, 647–648 (2013). · DOI
  28. Forbes, S.A. et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc. Hum. Genet. Chapter 10, Unit 10.11 (2008). · DOI · Paper page
  29. Lampson, B.L. et al. Rare codons regulate KRas oncogenesis. Curr. Biol. 23, 70–75 (2012). · DOI
  30. Schumacher, A.J., Nissley, D.V. & Harris, R.S. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl. Acad. Sci. USA 102, 9854–9859 (2005). · DOI
  31. Einav, U. et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 24, 6367–6375 (2005). · DOI
  32. Refsland, E.W. et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274–4284 (2010). · DOI · Paper page
  33. Menendez, D., Shatz, M. & Resnick, M.A. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 25, 85–92 (2013). · DOI
  34. Zhou, L. et al. Activation of toll-like receptor-3 induces interferon-λ expression in human neuronal cells. Neuroscience 159, 629–637 (2009). · DOI
  35. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100, 1–441 (2012).
  36. Lopes, M., Foiani, M. & Sogo, J.M. Multiple mechanisms control chromosome integrity after replication fork uncoupling and restart at irreparable UV lesions. Mol. Cell 21, 15–27 (2006). · DOI · Paper page
  37. Pagès, V. & Fuchs, R.P. Uncoupling of leading- and lagging-strand DNA replication during lesion bypass in vivo. Science 300, 1300–1303 (2003). · DOI · Paper page
  38. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688–695 (2010). · DOI · Paper page
  39. Bunting, S.F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010). · DOI · Paper page
  40. Bando, M. et al. Csm3, Tof1, and Mrc1 form a heterotrimeric mediator complex that associates with DNA replication forks. J. Biol. Chem. 284, 34355–34365 (2009). · DOI
  41. Katou, Y. et al. S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex. Nature 424, 1078–1083 (2003). · DOI · Paper page
  42. Yates, L.R. & Campbell, P.J. Evolution of the cancer genome. Nat. Rev. Genet. 13, 795–806 (2012). · DOI · Paper page
  43. Chapman, M.A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467–472 (2011). · DOI · Paper page
  44. Berger, M.F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214–220 (2011). · DOI · Paper page
  45. Harfe, B.D. & Jinks-Robertson, S. DNA polymerase ζ introduces multiple mutations when bypassing spontaneous DNA damage in Saccharomyces cerevisiae. Mol. Cell 6, 1491–1499 (2000). · DOI
  46. Sakamoto, A.N. et al. Mutator alleles of yeast DNA polymerase ζ. DNA Repair (Amst.) 6, 1829–1838 (2007). · DOI

Cited by

See all 1,167

Metadata

Authors
Roberts, S. A., Lawrence, M. S., Klimczak, L. J., Grimm, S. A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G. V., Carter, S. L., Saksena, G., Harris, S., Shah, R. R., Resnick, M. A., Getz, G., & Gordenin, D. A.
Venue
Nature Genetics
Publisher
Springer Science and Business Media LLC
Published
2013-07-14
Volume
45
Issue
9
Pages
970-976
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
DOI
10.1038/ng.2702
OpenAlex
W2003665515
Cited by
1,167
References
5
FWCI
27.32
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.